Igor Splawski PhD, was appointed as Chief Scientific Officer (CSO) in July 2020. Previously, he was at the Novartis Institutes for BioMedical Research (NIBR) in Cambridge, MA, where he worked on ten clinical compounds with eight positive proof-of-concept trials. Since 2018, he was an Executive Director and Site Head of the NIBR Biologics Center. Igor led more than 100 scientists, whose efforts included identification and evaluation of protein, mRNA, and adeno-associated virus (AAV) drug targets through human genetics in collaboration with an international clinical group. He was an Assistant Professor at Harvard Medical School from 2005 to 2008. Igor has a PhD in human genetics from the University of Utah and an MSc in biotechnology from Sofia University. He is an inventor on 28 patents, and author of 22 research publications.